Insider Trading History of Galletta Christopher

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Galletta Christopher since 2010. This trader's CIK number is 1486099. At the time of last reporting, Galletta Christopher was the See Remarks of Trevi Therapeutics, Inc.. (stock ticker symbol TRVI). Also see all insider trading activities at Trevi Therapeutics, Inc..

Note that in the past Galletta Christopher also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Transact Technologies Inc (TACT) by Galletta Christopher

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2012 TACT 0 $0 0 $0 500 $1,090
2011 TACT 0 $0 850 $10,675 600 $2,226
2010 TACT 0 $0 1,600 $14,688 1,600 $5,936

Yearly summary of insider trading at Trevi Therapeutics, Inc. (TRVI) by Galletta Christopher

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2024 TRVI 0 $0 0 $0 15,000 $7,665


Insider trading activities at 2 companies by Galletta Christopher:

1. Transact Technologies Inc (TACT)

2. Trevi Therapeutics, Inc. (TRVI)

Table 1. Insider trading of Transact Technologies Inc (TACT) by Galletta Christopher

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2012-01-02 TACT Option Ex 500 2.18 1,090
2011-05-11 TACT Sale 600 12.43 7,458
2011-05-10 TACT Sale 250 12.87 3,217
2011-05-11 TACT Option Ex 600 3.71 2,226
2010-11-12 TACT Sale 1,600 9.18 14,688
2010-11-12 TACT Option Ex 1,600 3.71 5,936

Table 2. Insider trading of Trevi Therapeutics, Inc. (TRVI) by Galletta Christopher

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2024-12-13 TRVI Option Ex 15,000 .51 7,665

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Galletta Christopher (See Remarks of Trevi Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.